CAR-T Cell Therapy in China

China has had more registered CAR-T clinical trials on ClinicalTrials.gov than any other country since September 2017 [1]. By June 2026, China's National Medical Products Administration had approved eight CAR-T products, all made from the patient's own cells [2]. They include satri-cel, the world's first CAR-T approved for a solid tumour, for advanced stomach cancer [2] [18]. Reported list prices are about RMB 990,000 to 1.29 million per dose [3] [4] [5]. Chinese regulations restrict sending patient cells abroad for manufacturing [8], so CAR-T treatment means staying in China for several weeks. International patients have already been treated with approved products in Shanghai [15] [16]. We can connect you with Prof. He Huang and Dr. Yongxian Hu of the First Affiliated Hospital of Zhejiang University for blood cancers, and with Prof. Lin Shen of Peking University Cancer Hospital for CAR-T in stomach cancer.

Specialists
Prof. He Huang, Dr. Yongxian Hu, Prof. Lin Shen
Hospitals
The First Affiliated Hospital, Zhejiang University School of Medicine; Peking University Cancer Hospital
Typical time in China
About 2–3 months
Written opinion
US$199, within 5 working days, with a cost estimate
Upload records for a specialist opinionNo travel needed for the opinion. Full refund if the specialist cannot accept your case.

What is CAR-T therapy?

T cells are collected from your blood, fitted in a laboratory with a chimeric antigen receptor (CAR) that recognises the cancer, multiplied, and infused back. One treatment includes cell collection, manufacturing, a short course of chemotherapy to prepare the body, the infusion and close monitoring in hospital.

CAR-T products approved in China (selection)

ProductTargetApproved in ChinaApproved useReported price per dose
Axicabtagene ciloleucel (Yikaida)CD19June 2021, China's first [3]Relapsed or refractory large B-cell lymphoma TBCRMB 1.2 million [3] [13]
Relmacabtagene autoleucel (Carteyva)CD19September 2021 [4]Relapsed or refractory large B-cell lymphoma [8]RMB 1.29 million [3] [4]
Equecabtagene autoleucel (Fucaso)BCMAJune 2023 [6]Relapsed or refractory multiple myeloma after at least three lines of therapy [6]RMB 1.166 million [3]
Inaticabtagene autoleucelCD19November 2023 [3]Adult relapsed or refractory B-cell acute lymphoblastic leukaemia [14]RMB 999,000 [3]
Zevorcabtagene autoleucelBCMAFebruary 2024 [7]Relapsed or refractory multiple myeloma after at least three lines of therapy [7]RMB 1.15 million [2]
Satricabtagene autoleucel (satri-cel)CLDN18.2June 2026, the world's first CAR-T for a solid tumour [2]CLDN18.2-positive, HER2-negative advanced stomach or gastro-oesophageal junction adenocarcinoma after at least two lines of treatment [2]RMB 990,000 [5]

Prices are manufacturers' list or launch prices. Hospital costs for assessment, chemotherapy and monitoring are added and are included in your cost estimate. For comparison, US list prices are about US$273,000–475,000 [17].

Research by Chinese teams

CancerStudyResult
Multiple myeloma (BCMA)LEGEND-2, the first-in-human trial of LCAR-B38M, run in China with 74 patients; the product is now approved in many countries as ciltacabtagene autoleucel, J Hematol Oncol 2024 [10]Median follow-up 65.4 months; 5-year overall survival 49.1% and progression-free survival 21.0%
Multiple myeloma (BCMA)Equecabtagene autoleucel, FUMANBA-1, 103 patients, 14 centres, JAMA Oncology 2024 [9]Overall response 96.0%; complete response or better 74.3%; 12-month progression-free survival 78.8%
Large B-cell lymphoma (CD19)Relmacabtagene autoleucel, RELIANCE, 59 patients treated, Cancer Medicine 2021 [8]Overall response at 3 months 60.3%
Gastrointestinal cancers (CLDN18.2)Satri-cel phase 1 final results, 98 patients, Nature Medicine 2024 [12]Overall response 38.8%; median overall survival 8.8 months
Stomach cancer (CLDN18.2), after at least two linesSatri-cel vs physician's choice, randomised, 156 patients, Lancet 2025 [11]Median progression-free survival 3.25 vs 1.77 months; the first randomised CAR-T trial in a solid tumour

More on stomach cancer: stomach cancer treatment in China.

The treatment process

StepWhat happensAbout how long
AssessmentConfirm the diagnosis and previous treatments; check organ functionAbout 1 week
Cell collectionT cells are collected by apheresis1 day
ManufacturingCAR-T cells are made in the laboratory; "bridging" treatment may be needed meanwhileAbout 5 weeks from collection to infusion in one reported case [15]
Preparatory chemotherapyUsually fludarabine and cyclophosphamide daily for 3 days [8]3 days
Infusion and monitoringMonitoring in hospital for cytokine release syndrome and neurotoxicity, then staying near the hospitalAbout 3 weeks in hospital after infusion in the same case [15]

Plan for about 2–3 months in China in total. These are typical estimates; your written opinion gives the plan for your case.

Specialists we can connect you with

These specialists can provide a written opinion or an outpatient appointment through us. Approved products are given only at hospitals certified by the manufacturer. This page was written by our medical team based on published research.

Photo TBC

Prof. He Huang

Director, Institute of Hematology, Zhejiang University; Head of the Bone Marrow Transplantation Center; Chief Physician · Bone Marrow Transplantation Center, Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine

CAR-T cell therapy and stem cell transplantation for leukaemia, lymphoma and multiple myeloma

  • Nature 2022 (senior author): Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL — PubMed 36045296
  • Lancet Haematology 2023 (senior author): GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial — PubMed 36725117
  • Cell Research 2022 (senior author): Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study — PubMed 36151216
Request a written opinion from Prof. He Huang
Dr. Yongxian Hu

Dr. Yongxian Hu

Chief Physician · Bone Marrow Transplantation Center, Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine

CAR-T cell therapy and allogeneic stem cell transplantation for blood cancers

  • New England Journal of Medicine 2024 (first author): Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis — PubMed 38657244
  • Clinical Cancer Research 2021 (first author): CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia — PubMed 33627493
Request a written opinion from Dr. Yongxian Hu
Prof. Lin Shen

Prof. Lin Shen

Director, Department of Gastrointestinal Oncology, and Director, Phase I Clinical Trial Ward; Professor and Chief Physician · Department of Gastrointestinal Oncology, Peking University Cancer Hospital

Drug treatment of stomach and other gastrointestinal cancers, including immunotherapy and CLDN18.2 CAR-T therapy

  • Lancet 2025 (senior author): Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial — PubMed 40460847
  • Nature Medicine 2025 (first author): First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial — PubMed 39843940
  • Nature Medicine 2024 (senior author): Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results — PubMed 38830992
Request a written opinion from Prof. Lin Shen

Frequently asked questions

Which cancers can CAR-T treat in China?

Approved CAR-T products in China are mainly for blood cancers: B-cell lymphoma, B-cell acute lymphoblastic leukaemia and multiple myeloma. Since June 2026 there is also one for CLDN18.2-positive advanced stomach cancer [2]. For other solid tumours, CAR-T is available only in clinical trials.

How much does CAR-T cost in China?

Reported list prices for approved products are about RMB 990,000 to 1.29 million per dose [3] [4] [5]. The full treatment episode, including assessment, cell collection, chemotherapy and hospital monitoring, costs more and is included in your cost estimate. US list prices are about US$273,000–475,000 [17].

Can international patients receive CAR-T in China?

Yes. A patient from Singapore received axicabtagene ciloleucel in Shanghai in 2023 [15], Ruijin Hospital in Shanghai has treated a patient from South Africa with multiple myeloma [16], and one Shanghai provider reported treating more than 20 foreign patients from 12 countries [17]. Chinese regulations restrict sending patient material abroad for CAR-T manufacturing [8], so cell collection, infusion and monitoring all take place in China.

Can I join a CAR-T clinical trial in China?

It depends on each trial's protocol and ethics approval. We check eligibility trial by trial with the specialists.

What are the risks?

Cytokine release syndrome is common: 93.2% in FUMANBA-1, almost all grade 1–2 [9], and 95% in the satri-cel randomised trial [11]. Neurotoxicity occurred in 1.9% in FUMANBA-1 [9]. Low blood counts and infections can also occur, which is why patients stay close to an experienced centre after infusion.

How long will I need to stay in China?

Plan for about 2–3 months. In one reported case, cells were infused about 5 weeks after collection and the patient left hospital 3 weeks after infusion [15].

How well does CAR-T work?

It depends on the cancer and the product. See the table of Chinese trial results above.

I do not speak Chinese. How will I communicate?

Our medical coordinators work with you in English (or Russian) throughout, and an interpreter accompanies you to appointments.

Can I find out whether I am eligible before travelling?

Yes. Upload your records and one of the specialists above will give a written opinion on whether CAR-T is an option.

Find out whether CAR-T is an option for you

Upload your diagnosis, treatment history and recent test results. A medical coordinator will reply within 24 hours and pass your records to the specialist.

Start here

References

  1. Wei J, et al. Clinical development of CAR T cell therapy in China: 2020 update. Cell Mol Immunol. 2021. PMID 32999455. (China has had the most registered CAR-T trials on ClinicalTrials.gov since September 2017; 357 by June 2020, plus about 150 on ChiCTR.) https://pubmed.ncbi.nlm.nih.gov/32999455/
  2. 21st Century Business Herald, 22 June 2026: approval of satricabtagene autoleucel, the world's first CAR-T approved for a solid tumour; eight CAR-T products approved in China, all autologous; zevorcabtagene autoleucel priced at RMB 1.15 million per dose (in Chinese). https://m.21jingji.com/article/20260622/herald/b2fac415c3ee78b537e04a93ae0fafd2_zaker.html
  3. Cailian Press, 13 January 2024: axicabtagene ciloleucel approved on 22 June 2021 as China's first CAR-T; equecabtagene autoleucel (June 2023) and inaticabtagene autoleucel (November 2023); reported prices RMB 1.2 million, 1.29 million, 1.166 million and 999,000 (in Chinese). https://www.cls.cn/detail/1569960
  4. Cailian Press, 1 March 2024: zevorcabtagene autoleucel approved as China's fifth CAR-T; relmacabtagene autoleucel approved September 2021 at RMB 1.29 million per dose (in Chinese). https://www.cls.cn/detail/1608760
  5. Huxiu: satricabtagene autoleucel priced at RMB 990,000 (in Chinese). https://www.huxiu.com/article/4869701.html
  6. Keam SJ. Equecabtagene autoleucel: first approval. Mol Diagn Ther. 2023. PMID 37658205. https://pubmed.ncbi.nlm.nih.gov/37658205/
  7. Dhillon S. Zevorcabtagene autoleucel: first approval. Mol Diagn Ther. 2024. PMID 38888762. https://pubmed.ncbi.nlm.nih.gov/38888762/
  8. Ying Z, et al. Relmacabtagene autoleucel (relma-cel) CD19 CAR-T therapy for adults with heavily pretreated relapsed/refractory large B-cell lymphoma in China. Cancer Med. 2021. PMID 33382529. https://pubmed.ncbi.nlm.nih.gov/33382529/
  9. Li C, et al. Equecabtagene autoleucel in patients with relapsed or refractory multiple myeloma: the FUMANBA-1 nonrandomized clinical trial. JAMA Oncol. 2024. PMID 39509090. https://pubmed.ncbi.nlm.nih.gov/39509090/
  10. Xu J, et al. Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial. J Hematol Oncol. 2024. PMID 38659046. https://pubmed.ncbi.nlm.nih.gov/38659046/
  11. Qi C, et al. Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01). Lancet. 2025. PMID 40460847. https://pubmed.ncbi.nlm.nih.gov/40460847/
  12. Qi C, et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results. Nat Med. 2024. PMID 38830992. https://pubmed.ncbi.nlm.nih.gov/38830992/
  13. The Paper, 26 October 2021: proposed Guangdong listing price of RMB 1.2 million for axicabtagene ciloleucel (in Chinese). https://www.thepaper.cn/newsDetail_forward_15081815
  14. Wang Y, et al. Inaticabtagene autoleucel in adult relapsed or refractory B-cell acute lymphoblastic leukemia. Blood Adv. 2025. PMID 39626300. https://pubmed.ncbi.nlm.nih.gov/39626300/
  15. Jiahui International Hospital, Shanghai: first foreign patient in China treated with axicabtagene ciloleucel — cells collected 19 July 2023, infused 21 August 2023, discharged 13 September 2023, three weeks after infusion. https://jiahui.com/en/news/133
  16. China Daily, 4 February 2026: "Foreigners check-in to China for hospital expertise" — a patient from South Africa with multiple myeloma treated with CAR-T at Ruijin Hospital, Shanghai. https://www.chinadaily.com.cn/a/202602/04/WS69827ebba310d6866eb374ac_1.html
  17. Yicai Global, 5 December 2025: a Shanghai provider reported treating more than 20 foreign CAR-T patients from 12 countries; US list prices cited at USD 273,000–475,000 and China from about RMB 1 million. https://www.yicaiglobal.com/news/faster-cheaper-access-is-turning-china-into-a-car-t-therapy-hub-for-cancer-patients
  18. China News Service, 22 June 2026, citing the Shanghai Science and Technology Commission: satricabtagene autoleucel approved as the world's first CAR-T therapy for solid tumours (in Chinese). https://www.chinanews.com.cn/sh/2026/06-22/10645095.shtml